At long last, the Trump administration’s much-ballyhooed tariffs on pharmaceutical imports are materializing in a trade deal ...

After a first half that saw Publicis Groupe snap up six companies around the world, the advertising giant is continuing its ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase inhibitor on the market, Eli Lilly’s Jaypirca, has shown its chops in a ...

Monday, the FDA said Sarepta may resume treating ambulatory DMD patients with Elevidys. The recommendation comes just 10 days ...

After what Bavarian Nordic described as “intense negotiations,” the Danish vaccines maker has agreed to be acquired by a ...

Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...